Industry News

Eyevensys Engages in Partnerships to Develop New Gene Therapy Device to Treat Eye Diseases

Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, has entered into multi-year strategic agreements with US-based medical device manufacturers Phillips-Medisize and Minnetronix

Eyevensys Engages in Partnerships to Develop New Gene Therapy Device to Treat Eye Diseases
September 28, 2021
Haag-Streit UK Introduces MR Q Combo Laser System in the UK

Haag-Streit UK, a leading manufacturer and distributor of ophthalmic, optometry, and orhtopic equipment, has announced the launch of the MR Q Combo laser system in the UK.

Haag-Streit UK Introduces MR Q Combo Laser System in the UK
September 24, 2021
Neurolens and DVI Form Collaboration to Expand Prism Specificity

In the light of growing prevalence of eye misalignment, Neurolens and Digital Vision, Inc. (DVI) have formed a collaboration to expand the prism field from 1/8th prism diopter to 1/100th prism diopter for all Neurolens designs.

Neurolens and DVI Form Collaboration to Expand Prism Specificity
September 23, 2021
Pharos Capital Acquires Vantage Outsourcing to Build New Ophthalmology Services Platform

Pharos Capital Group, a middle-market private equity firm based in Dallas and Nashville, has acquired Vantage Outsourcing, a leading cataract surgical service provider, in line with its mission to improve health care services in rural and underserved area

Pharos Capital Acquires Vantage Outsourcing to Build New Ophthalmology Services Platform
September 23, 2021
Tim Largen Joins Aurion Biotech As Vice President of Manufacturing

Aurion Biotech, a clinical-stage biotech company, has appointed Tim Largen as VP of manufacturing.

Tim Largen Joins Aurion Biotech As Vice President of Manufacturing
September 21, 2021
Glaukos Enters into Licensing Agreement with Attillaps Holdings

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, has entered into licensing agreement with Attillaps Holdings,

Glaukos Enters into Licensing Agreement with Attillaps Holdings
September 21, 2021
Visus Expands Ophthalmic Drug Portfolio for Corneal Wound Healing, Glaucoma and AMD

Visus Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, unveiled additional ophthalmic drug candidates (VT-201) with applications in development

Visus Expands Ophthalmic Drug Portfolio for Corneal Wound Healing, Glaucoma and AMD
September 17, 2021
Optimism Health Group Expands its Footprint with VisionCall acquisition

Optimism Health Group, a healthcare investment business, has recently completed the acquisition of VisionCall, the UK's leading provider of eye care services in care homes. The acquisition came in line with Optimism’s plans to expand its footprint in the

Optimism Health Group Expands its Footprint with VisionCall acquisition
September 15, 2021
Daha fazla